Zoetis (ZTS) gained 2.37% in the latest session, outperforming the S&P 500's 0.6% gain. However, the animal health company faces headwinds with forecasted EPS declining 10.59% and revenue expected to drop 3.66% in the upcoming quarter. The stock holds a Zacks Rank of #4 (Sell) with no recent estimate revisions, and trades at a Forward P/E of 11.78, below its industry average.

Phibro Animal Health (PAHC) is gaining momentum from strong Animal Health segment growth, driven by the Zoetis MFA acquisition, vaccine expansion, and mineral nutrition demand recovery. However, the company faces headwinds from macroeconomic risks, trade policy uncertainties, and foreign exchange volatility that continue to pressure reported results.

Vietnam's veterinary vaccine import market is expanding due to growing livestock and aquaculture sectors, with imports valued at US$172 million in 2024. The market remains highly dependent on imported vaccines, particularly from the US (34.6%), China (12.8%), and Netherlands (8.7%). International companies like Zoetis, MSD Animal Health, and Boehringer Ingelheim maintain strong positions, while foreign investment opportunities are emerging through joint ventures and local manufacturing partnerships.

Zoetis (ZTS) ended trading at $69.10, down 1.05% from the previous day and 8.32% over the past month. The animal health company faces a negative earnings outlook with forecasted EPS down 10.59% and revenue down 3.66% for the upcoming quarter. The stock has been assigned a Zacks Rank of #5 (Strong Sell), though it trades at a discount to its industry average with a Forward P/E of 11.26.

The global veterinary diagnostics market is projected to grow from USD 11.76 billion in 2025 to USD 30.78 billion by 2035, driven by increasing pet ownership, zoonotic disease surveillance, and advancements in point-of-care testing and molecular diagnostics. North America leads with 39% market share, while Asia-Pacific shows the fastest growth. Reagents & kits dominate products, while companion animals represent 61% of the market.

Zoetis stock declined 2.22% to $71.40, underperforming the broader market gains. The animal health company faces headwinds with projected EPS down 10.59% and revenue down 3.66% for the upcoming quarter. The company holds a Zacks Rank of #5 (Strong Sell) despite trading at a Forward P/E discount to its industry average.

A comprehensive 249-page veterinary diagnostics market report covering 15 countries and 32 companies has been released, forecasting market trends through 2030. The report analyzes growth drivers including pet ownership patterns, agricultural modernization, and the One Health movement, while examining competitive positioning of major players like IDEXX, Zoetis, Antech, Roche, and Thermo Fisher across various diagnostic assay types, animal categories, and applications.

The global veterinary medical devices market is projected to grow from $6.5 billion in 2024 to $9.1 billion by 2030 at a 6.1% CAGR, driven by pet humanization trends, expanding pet insurance coverage, and AI-enabled diagnostic innovations. North America dominates with 55.9% market share, while emerging markets present long-term growth opportunities.

Class action lawsuits have been filed against AeroVironment, Calix, Zoetis, and Lucid Group, alleging that company executives made materially false statements and failed to disclose material adverse facts about their businesses. The lawsuits cover various issues including understated competition, supply chain problems, declining product adoption, and manufacturing disruptions. Lead plaintiff deadlines range from July 27-28, 2026.

A securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products during January 2025 to May 2026. The lawsuit claims the company failed to disclose weakening veterinarian adoption of its Librela pain treatment following FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining sales in dermatology products Apoquel and Cytopoint. Investors who purchased securities during this period may be eligible for compensation.

A class action lawsuit has been filed against Zoetis, Inc. for allegedly making materially false statements and failing to disclose material adverse facts during the period from January 14, 2025 to May 6, 2026. The complaint alleges that Zoetis concealed weakening veterinarian adoption of its Librela product due to FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining market share for dermatology products Apoquel and Cytopoint. Investors have until July 27, 2026 to apply to be appointed as lead plaintiff.

A securities fraud class action lawsuit has been filed against Zoetis Inc. for allegedly making materially false statements and failing to disclose material adverse facts about its business. The lawsuit covers investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026. The company's stock declined significantly following three earnings announcements that revealed weakened demand in its Companion Animal portfolio, increased competition, and declining sales of key products including Librela, Simparica Trio, Apoquel, and Cytopoint. The deadline to file a lead plaintiff motion is July 27, 2026.